Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel with Cisplatin and RT for Cervical Cancer
NCT04017377Phase 1Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in Cervical Cancer (CC), sponsored by Peking University Third Hospital. Primary endpoint: Maximum Tolerated Dose/Recommended Dose up to 5 weeks. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04017377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017377.